Table 3.

Multivariable Analyses in Patients Alive and Free of Disease at 12 Months

Variable	OS		DFS		Relapse		NRM
	HR	p	HR	p	HR	p	HR	p
Age
≥50	Ref		Ref		Ref		Ref
<40	0.45	<0.0001	0.57	0.001	0.7	0.2	0.6	0.08
40-49	0.65	0.01	0.82	0.2	1.0	0.9	1.5	0.10
Sex
Female	Ref		Ref		Ref		Ref
Male	1.20	0.2	1.07	0.58	0.9	0.4	1.4	0.1
Income quartile
Q1	Ref		Ref		Ref		Ref
Q2	1.32	0.17	1.22	0.26	0.9	0.8	1.6	0.08
Q3	1.03	0.89	0.94	0.72	0.8	0.5	1.2	0.6
Q4	1.13	0.56	0.97	0.89	0.8	0.3	1.3	0.33
Race
Non-Caucasian	Ref		Ref		Ref		Ref
Caucasian	0.89	0.69	0.80	0.38	0.7	0.3	0.9	0.9
CMV+ (donor or recipient)
Negative	Ref		Ref		Ref		Ref
Positive	1.19	0.24	1.08	0.55	0.8	0.3	1.4	0.1
Diseasea
Low risk	Ref		Ref		Ref		Ref
Int risk	2.16	0.003	2.02	0.001	2.2	0.008	1.6	0.2
High risk	3.28	<0.0001	2.38	0.0003	3.3	0.0002	1.2	0.6
Donor sex
Male	Ref		Ref		Ref		Ref
Female	0.94	0.64	0.93	0.54	0.8	0.2	1.1	0.6
Stage at SCTb
Low risk	Ref		Ref		Ref		Ref
Int risk	1.80	0.002	1.6	0.006	1.9	0.006	1.2	0.5
High risk	1.93	0.0003	1.7	0.001	2.2	0.0004	1.2	0.6
Donor type
MUD	Ref		Ref		Ref		Ref
MRD	0.98	0.05	0.98	0.89	1.8	0.003	0.5	0.001
Mismatched	0.84	0.60	0.84	0.50	0.9	0.7	0.8	0.6
Graft source
BM	Ref		Ref		Ref		Ref
UCB	1.94	0.18	1.94	0.12	3.3	0.039	0.5	0.4
PB	1.11	0.66	0.83	0.36	0.5	0.018	1.5	0.3
Conditioning
Myeloablative	Ref		Ref		Ref		Ref
Reduced intensity	0.76	0.17	0.97	0.86	1.7	0.04	0.5	0.023
GVHD prophylaxis
CnI combination	Ref		Ref		Ref		Ref
T-cell depletion	1.11	0.65	1.00	1.00	0.8	0.6	1.3	0.4
Rapa containing	1.21	0.28	1.1	0.57	1.0	0.9	1.2	0.4
Protocol
Off protocol HSCT	Ref		Ref		Ref		Ref
On protocol HSCT	0.80	0.15	0.87	0.34	0.6	0.028	1.4	0.11
Year of HSCT
< 2002	Ref		Ref		Ref		Ref
≥ 2002	0.76	0.26	0.86	0.49	0.7	0.14	1.1	0.8
Driving time
≤40 mins	Ref		Ref		Ref		Ref
41-159 mins	1.3	0.14	1.2	0.49	0.9	0.6	1.4	0.2
≥160 mins	1.8	0.004	1.5	0.03	1.3	0.3	1.7	0.076

^aLow risk disease: Benign hematological disease, low grade NHL, CLL Intermediate risk disease: MDS, MM, high grade NHL, HL, CML, MPD High risk disease: AML, ALL, other

^bLow risk stage: CR1, CR2 Intermediate risk stage: Untreated, PR High risk stage: Relapse, CR 3, induction failure